Menu Search
Equities

Azenta Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BA3:FRA

Azenta Inc

Actions
  • Price (EUR)23.60
  • Today's Change-0.600 / -2.48%
  • Shares traded67.00
  • 1 Year change-55.05%
  • Beta1.4029
Data delayed at least 15 minutes, as of Feb 06 2026 14:45 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

  • Revenue in USD (TTM)594.95m
  • Net income in USD28.69m
  • Incorporated1994
  • Employees3.00k
  • Location
    Azenta Inc200 Summit Drive, 6Th FloorBURLINGTON 01803United StatesUSA
  • Phone+1 (978) 262-2400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.azenta.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.